H.C. Wainwright lowered the firm’s price target on Ensysce Biosciences to $7 from $9 and keeps a Buy rating on the shares. The analyst says the company may choose to raise capital in the coming 12 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENSC: